By Fineline Cube 
China-based CANbridge Pharmaceuticals Inc., (HKG: 1228) announced that the first prescription of its Geruining (velaglucerase beta), a self-developed first-in-class enzyme replacement therapy (ERT) for Type I and III Gaucher disease, has been administered at Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. This marks the official entry of the first domestically developed ERT drug for this condition into clinical use.
Geruining: Mechanism of Action
Geruining is administered via intravenous infusion to specifically supplement the deficient glucocerebrosidase (GCase) in the lysosomes of Gaucher disease patients. It provides a targeted treatment approach for patients suffering from this rare genetic disorder.
Indication Coverage and Clinical Data
Among currently approved Gaucher disease treatments in China, Geruining has the broadest indication coverage. It is suitable for both Type I and III Gaucher disease patients, including children and adults who are unresponsive or intolerant to other therapies. Clinical data demonstrated that after nine months of treatment, Geruining achieved a 35.32% reduction in spleen volume and a 2.17 g/dL increase in hemoglobin levels.-Fineline Info & Tech